volume, hyponatremia, hypercalcemia, hyperglycemia, dyslipidemia) [9] . Regarding the electrolyte imbalances, thiazide-induced hyponatremia is certainly an important medical condition, that is regularly present in the internal medicine departments and it causes substantial morbidity to frail patients, often elderly, who are taking hydrochlorothiazide, in subgroups of patients [10, 11] . Equally not yet well understood is the mechanism by which hydrochlorothiazide interferes with the glucose homeostasis [12] [13] [14] . There is also a whole range of side effects, fortunately rarer, but described in the medical literature, ranging from the appearance of lupus [15] , interstitial lung disease [16] , even severe allergic states [17], pulmonary edema [18][19][20], all conditions linked to immunological changes induced by the molecule itself. The effect on the sense organs (hypoacusis) is more known and less rare (although investigated with low frequency, especially in the elderly subjects), with various reports from the organs of vigilance drug, for which there are well defined indications for the diagnosis of this adverse event (Austin Bradford-Hill criteria, Naranjo criteria), well applied in pharmacovigilance [21,22].
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Pharmacovigilance in Italy
With regard to this aspect, it is worth mentioning
Safety of Hydrochlorothiazide in the Real World: A Commentary on the Italian Medicines Agency (AIFA) Pronouncements
Background Thiazide diuretic drugs are the most commonly used molecules for the treatment of systemic hypertension. Despite their established role in the treatment of this disease, well recognized by the guidelines of national (such as the Italian Society of Cardiology -SIC -for example, which incorporates the directives of the European Society of Cardiology -ESC -) scientific societies [1,2] -including those that operate specifically in the setting of the General Medicine [3, 4] -that international scientific societies [5] [6] [7] [8] , with recognized effect and good class of recommendation, nevertheless in recent times new advice has arisen from studies present in the literature that have undermined its safety and warned the clinician of the dangers concerning their use. In particular, our attention focused on a molecule such as hydrochlorothiazide.
Known Adverse Events of Hydrochlorothiazide
Several evidences have shown that hydrochlorothiazide therapy in chronic renal disease with advanced grade of kidney insufficiency leads to deleterious effects, as the adverse effects of this therapy are reported (worsening of renal function, depletion of water use of other types of diuretic and other antihypertensive drugs was not associated with non-melanomatous skin tumors. Another study showed a possible association between labial squamous cell carcinoma and the exposure to this thiazide, in 633 cases compared to 63,067 controls, with a cumulative dose-response relationship with adjusted OR of 2.1 (95% CI : 1.7-2.6) which increased up to OR 3.9 (3.0-4.9) for patients who used it at high dose (~ 25.000 mg) and a OR 7.7 (5.7-10.5) for the highest cumulative dose (~ 100,000 mg) [33] . Finally, a recent study, conducted with the evaluation of different databases (PubMed, EMBASE, Cochrane Library), would confirm the association with increased risk of skin cancers, especially squamous cell carcinoma (underlining the need for further studies to confirm the results) [34] . The AIFA report concluded the report by inviting the physicians to the following prescriptive behaviors and to adopt the following precautions: information on the risk of non-melanoma skin cancers for patients taking hydrochlorothiazide, alone or in combination with other drugs, with the regular control and self-control of the skin for the early identification of any new lesions or changes to existing lesions, with notification to your doctor of any suspected skin lesion; examination of suspected skin lesions both from a clinical but also histological point of view, using the bioptic exam; warning patients about the limitation of exposure to sunlight/UV rays, with the use of adequate protection when exposed to sunlight/UV rays, to minimize the risk of skin cancers; careful evaluation and discernment on the prescription/use of hydrochlorothiazide in patients who have had a previous skin cancer.
Conclusions
Recent studies showed the presence of a cumulative dose-dependent association between hydrochlorothiazide and non-melanoma skin cancers. There was a statement with an information note issued by the European/Italian monitoring and surveillance organizations (European Medicines Agency -EMA -and AIFA). There is a need for the integration of pharmacological-epidemiological data and those data coming from the registers, the various databases and the studies already present in the literature with data collected in the real world, both in the academic environment but even more so in the field, especially from the databases in possession of general practitioners, to have as far as possible an objective picture of the situation.
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